Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients

NCT04466839 | Completed

• 1 other identifier: RC31/20/0193
• Study Type: observational
• Target: 411
• Locations: 1 country
• Sites: 8

Brief Summary

The consequences of COVID-19 in these already fragile patients should be evaluated. It will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. These consequences can be assessed by the end of confinement and 6 months after the latter is lifted.

Conditions

Parkinson Disease; COVID

Keywords

Parkinson Disease,; COVID-19; Confinement

Outcome Measures

Primary Outcomes (1)

• Impact of containment related to the Covid-19 pandemic.

  To compare quality of life using Parkinson Disease Questionnaire-8 Items (PDQ-8 ), during the period of confinement linked to the Covid-19 pandemic and 6 months after the end of the pandemic in patients with idiopathic Parkinson's disease. The minimum value is "never" and maximum value is "always"

  6 months after the end of the pandemic

Secondary Outcomes (3)

• Conditions of containment during the Covid-19 pandemic.

  Day 1

• The number of patients infected or possibly infected with Covid-19

  6 months after the end of the pandemic

• Symptoms modifications

  6 months after the end of the pandemic

Study Arms (1)

parkinsonian patients

Cohort of parkinsonian patients followed by doctors from the Parkinson Expert Centers in teaching hospitals.

Other: Questionnaire and interview

Interventions

Questionnaire and interview OTHER

The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).

parkinsonian patients

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient followed by a doctor from the Parkinson Expert Center with idiopathic Parkinson's disease between 16/03/2020 and 16/05/2020.

You may qualify if:

• Patient followed by a doctor from the Parkinson Expert Center of the Toulouse University Hospital, Lille, Paris, Rouen, Nimes, Reims, Besancon, Marseille
• And with idiopathic Parkinson's disease
• Patients hospitalized or in consultation between 16/03/2020 and 16/05/2020.

You may not qualify if:

• Atypical parkinsonian syndrome
• Patient subject to a legal protection order (tutorship)
• Patient not wishing to answer questions

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (8)

Centre Hospitalier Régionale Universitaire de Besançon

Besançon, 25030, France

Location

Centre Hospitalier Universitaire Lille

Lille, 59037, France

Location

Centre Hospitalier Universitaire de Marseille

Marseille, 13385, France

Location

Centre Hospitalier Universitaire de Nîmes - Caremeau

Nîmes, 30029, France

Location

Centre Hospitalier Universitaire de la Pitié-Salpêtrière

Paris, 75013, France

Location

Centre Hospitalier Universitaire de Reims

Reims, 51100, France

Location

Centre Hospitalier Universitaire de Rouen

Rouen, 76031, France

Location

CHU Toulouse

Toulouse, 31000, France

Location

Related Publications (1)

• Fabbri M, Leung C, Baille G, Bereau M, Brefel Courbon C, Castelnovo G, Carriere N, Damier P, Defebvre L, Doe de Maindreville A, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F. A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. Parkinsonism Relat Disord. 2021 Aug;89:128-133. doi: 10.1016/j.parkreldis.2021.07.013. Epub 2021 Jul 13.

  PMID: 34293534 RESULT

MeSH Terms

Conditions

Parkinson Disease; COVID-19

Interventions

Surveys and Questionnaires; Interviews as Topic

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Fabienne ORY MAGNE

  University Hospital, Toulouse

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2020
• First Posted: July 10, 2020
• Study Start: July 2, 2020
• Primary Completion: December 18, 2020
• Study Completion: December 18, 2020
• Last Updated: September 14, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (8)